AstraZeneca will buy a Chinese biopharmaceutical company for up to $1.2 billion to expand its cell therapies pipelines, the Anglo-Swiss pharmaceutical company announced on Tuesday. It has entered into a definitive agreement to acquire Gracell Biotechnologies Inc.Read more https://www.theepochtimes.com/business/astrazeneca-to-acquire-chinese-firm-to-boost-cell-therapy-portfolio-5553253